Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.810
+0.260 (5.71%)
At close: Aug 7, 2026, 4:00 PM EDT
4.870
+0.060 (1.25%)
Pre-market: Aug 10, 2026, 8:27 AM EDT
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
377.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 69.21M |
| Fennec Pharmaceuticals | 51.00M |
| Foghorn Therapeutics | 36.74M |
| C4 Therapeutics | 34.86M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
| Lyell Immunopharma | 27.00K |
LXEO News
- 3 days ago - Lexeo Therapeutics management to meet with Cantor - TheFly
- 5 days ago - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy - GlobeNewsWire
- 5 weeks ago - Lexeo Therapeutics Transcript: Fireside chat - Transcripts
- 6 weeks ago - Lexeo Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan - TheFly
- 7 weeks ago - Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Transcript: Investor update - Transcripts
- 2 months ago - Lexeo Therapeutics Slides: Investor update - Filings